PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

• Status: Completed
• Trial end date: 2020-12-13
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Cadexomer iodine; Iodine; Povidone; Povidone-Iodine

Criteria

Inclusion Criteria:

• Diagnosis of COVID-19 by lab test within 5 days of study participation

Exclusion Criteria:

• Allergy to "iodine," shellfish, or food dye

• Receiving intranasal steroids

• Sinus surgery within 30 days of beginning the study

• Intubated at the time of enrollment

• Pregnancy

• Participation in other COVID-19 studies - to be determined on a case by case basis